Rolling Stone Magazine | 2020-01-24 09:49
A Weed Grows in Davos
At the World Economic Forum, cannabis is a commodity like any other — but these interested parties aren’t looking to get high
Here at the World Economic Forum in Davos, Switzerland, one sign that your international venture has reached a level of prominence is the appearance of a “house” bearing your name — a storefront to hang your hat, give away swag, and hold endless seminars while pumping champagne into would-be investors. There’s the Caspian Week digs, a storefront devoted to the economic interests of the Caspian Sea region, which one night featured female musicians apparently trying to re-create the 1986 Robert Palmer “Addicted To Love” video. My favorite was the Karnataka House, a one-stop-shop for all things commerce in Southwestern India that had a mysterious sign in its window proclaiming ‘Pizzeria Still Open.’
Investing.com | 2020-01-21 08:16
Economic Case For Cannabis Being Made In Davos As Pot Stocks Tick Higher
World leaders are not the only people in Davos, Switzerland, for the World Economic Forum this week. Movers and shakers within the cannabis sector from a cross-section of nations are there to rub shoulders with the political and economic heavyweights from around the globe to further the push of the cannabis industry.
CannTech Davos 2020 is hosting a two-day conference at Cannabis House, located in the heart of the Economic Forum, to focus attention on the economic role of cannabis and the growing industry around it and how they will play in the future of health care, international trade, investment and environmental and resource security and climate change.Read More...
yahoo! finance | 2020-01-21 02:07
Ehave Enters $88 Billion Mental Health Market
Ehave, Inc., (OTC Pink:EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that it has signed a Letter of Intent to acquire 100% of PsychedeliTech (“PsyTech”), a division of Tel Aviv, Israel based Israel Cannabis Limited (“iCAN”). The transaction is expected to close within 45 days. Upon closing of the transaction, iCAN Founder, Saul Kaye, will be appointed as a Chairman of Ehave’s to be formed subsidiary PsychedeliTech.
No Camels | 2019-12-05 10:38
After a Rough Year cannabis sector looks to separate the serious players from the opportunists in 2020
Global cannabis companies are ready to welcome 2020, hoping new regulations will pave the way for more canna-tech products and new marijuana businesses. Israeli canna-players, specifically, are marching into the new year with peak status in medical cannabis research.
Israel continues to be the go-to for cannabis’ potential benefits. The country is an established world leader in medical cannabis R&D, thanks to the pioneering work of Hebrew University of Jerusalem Professor Raphael Mechoulam and other scientists in Israel.
The WC | 2019-11-30 10:33
‘Western Cape perfectly positioned to drive the cannabis industry boom’
The Western Cape could be the future cannabis hub of Africa.
Cannabis experts, entrepreneurs and investors gathered this week at the CannaTech international conference in Cape Town.
CannaTech founder and chief executive of iCAN Israel, Saul Kaye said South Africa was one of just six countries in the world that were active in the cannabis industry and could be poised to seize a massive opportunity.
Yahoo! Finance | 2019-11-20 11:19
CannaTech Organizers Launch Psychedelics Conference: PsyTech
The use of psychedelic drugs to treat a host of mental health problems ranging from depression and anxiety, to addiction and PTSD, is gaining new favor in the scientific community. Similar to how attitudes about cannabis have pivoted in recent years, people are now rethinking of how psychedelics can be used in a therapeutic way.
Some of the most serious medical research institutions in the United States, including UCLA, John’s Hopkins and NYU, have been conducting clinical trials around psychedelics to understand how to alleviate the conditions and symptoms, which are often unresponsive to conventional treatment.
Saul Kaye, the founder and CEO of iCAN: Israel-Cannabis and CannaTech sees an opportunity in the changing professional and lay mind-set.